Author's response to reviews

Title: Ferric carboxymaltose with or without erythropoietin for the prevention of red-cell transfusions in the perioperative period of osteoporotic hip fractures: A randomized controlled trial. The PAHFRAC-01 project.

Authors:

Máximo Bernabeu-Wittel (wittel@cica.es)
Reyes Aparicio (reyesapa@yahoo.es)
Manuel Romero (manuelromeroj@gmail.es)
José Murcia-Zaragoza (murcia_jos@gva.es)
Rafael Monte-Secades (rafael.monte.secades@sergas.es)
Clara Rosso (claramari.rosso.sspa@juntadeandalucia.es)
Abelardo Montero (amontero@gencat.es)
María Melero-Bascones (m_doc@ono.com)
PAHFRAC-01 investigators (wittel@cica.es)

Version: 2 Date: 10 January 2012

Author's response to reviews: see over
Dear Sir:

Thank you very much for your consideration. We have revised the manuscript, corrected the issues you suggested, and adapted the style and format to the requirements of your Journal.

Specifically we have incorporated the NCT reference after the last sentence of the Abstract, and we have also incorporated The Competing Interests section. We have also minimally changed the Titles, and the references style.

Please find the attached revised version of our manuscript “FERRIC CARBOXYMALTOSE WITH OR WITHOUT ERYTHROPOIETIN FOR THE PREVENTION OF RED-CELL TRANSFUSIONS IN THE PERIOPERATIVE PERIOD OF OSTEOPOROTIC HIP FRACTURES: A RANDOMIZED CONTROLLED TRIAL. THE PAHFRAC-01 PROJECT.”

We hope, that this revised version of our manuscript will fulfil the requirements of BMC Musculoskeletal Disorders.

Yours sincerely:
Máximo Bernabeu-Wittel
Independent promoter of PAHFRAC-01 (Eudra-CT 2009-015865-30; ClinicalTrials.gov identifier: NCT01154491)
Department of Internal Medicine, Hospitales Universitarios Virgen del Rocío
Avenida Manuel Siurot s/n.
41013 SEVILLA, SPAIN
Phone: 34 955 013439. Fax: 34 955 013440
E-mail: wittel@cica.es